Literature DB >> 21118358

2009 Japanese Society for Dialysis Therapy guidelines for peritoneal dialysis.

.   

Abstract

The guidelines for peritoneal dialysis (PD) of the Japanese Society for Dialysis Treatment were prepared at 2009. Upon presenting a concrete frame of PD practiced in Japan, it aims to promote PD as a standardized therapy in Japan. Notably, the guidelines recommended combination therapy of PD and hemodialysis as a part of integrated renal replacement therapy for end-stage renal disease, as well as timely PD withdrawal by peritoneal degeneration in order to prevent progression of encapsulating peritoneal sclerosis.
© 2010 The Authors. Journal compilation © 2010 International Society for Apheresis.

Entities:  

Mesh:

Year:  2010        PMID: 21118358     DOI: 10.1111/j.1744-9987.2010.00901.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  19 in total

1.  The peritoneal equilibration test should be included in routine monitoring of peritoneal dialysis patients.

Authors:  V Liakopoulos; O Nikitidou; M Divani; K Leivaditis; G Antoniadi; N V Dombros
Journal:  Perit Dial Int       Date:  2012 Mar-Apr       Impact factor: 1.756

2.  Normal peritoneum after nine years of peritoneal dialysis with biocompatible dialysate: a case report.

Authors:  Y Kamijo; H Iida; K Saito; R Furutera; Y Ishibashi
Journal:  Perit Dial Int       Date:  2013 Nov-Dec       Impact factor: 1.756

3.  Morphological characteristics in peritoneum in patients with neutral peritoneal dialysis solution.

Authors:  Chieko Hamada; Kazuho Honda; Kunio Kawanishi; Hirotaka Nakamoto; Yasuhiko Ito; Tsutomu Sakurada; Yudo Tanno; Toru Mizumasa; Masanobu Miyazaki; Misaki Moriishi; Masaaki Nakayama
Journal:  J Artif Organs       Date:  2015-02-14       Impact factor: 1.731

4.  A load volume suitable for reaching dialysis adequacy targets in anuric patients on 4-exchange CAPD.

Authors:  Giovambattista Virga; Vincenzo La Milia; Roberto Russo; Luciana Bonfante; Gian Maria Iadarola; Stefano Maffei; Massimo Sandrini; Matthias Zeiler; Maurizio Nordio
Journal:  J Nephrol       Date:  2014-02-26       Impact factor: 3.902

5.  Matrix metalloproteinase-2 as a superior biomarker for peritoneal deterioration in peritoneal dialysis.

Authors:  Ichiro Hirahara; Eiji Kusano; Yoshiyuki Morishita; Makoto Inoue; Tetsu Akimoto; Osamu Saito; Shigeaki Muto; Daisuke Nagata
Journal:  World J Nephrol       Date:  2016-03-06

6.  Biocompatibility of a new PD solution for Japan, Reguneal™, measured as in vitro proliferation of fibroblasts.

Authors:  Bart Dioos; Goedele Paternot; Rose-Marie Jenvert; Annick Duponchelle; Mark R Marshall; Migaku Nakajima; Edward Ramirez Ganoza; James A Sloand; Anders P Wieslander
Journal:  Clin Exp Nephrol       Date:  2018-06-20       Impact factor: 2.801

7.  Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: recent clinical practice in Japan.

Authors:  Nobuhiro Ayuzawa; Yoshitaka Ishibashi; Yutaka Takazawa; Haruki Kume; Toshiro Fujita
Journal:  Perit Dial Int       Date:  2011-07-31       Impact factor: 1.756

8.  Encapsulating peritoneal sclerosis in the era of a multi-disciplinary approach based on biocompatible solutions: the NEXT-PD study.

Authors:  Masaaki Nakayama; Masanobu Miyazaki; Kazuho Honda; Kenji Kasai; Tadashi Tomo; Hidetomo Nakamoto; Hideki Kawanishi
Journal:  Perit Dial Int       Date:  2014-02-04       Impact factor: 1.756

9.  Japanese society for dialysis therapy renal data registry-a window through which we can view the details of Japanese dialysis population.

Authors:  Norio Hanafusa; Shigeru Nakai; Kunitoshi Iseki; Yoshiharu Tsubakihara
Journal:  Kidney Int Suppl (2011)       Date:  2015-06

10.  The association of very-low-density lipoprotein with ankle-brachial index in peritoneal dialysis patients with controlled serum low-density lipoprotein cholesterol level.

Authors:  Eiichiro Kanda; Masumi Ai; Mitsuyo Okazaki; Yoshitaka Maeda; Sei Sasaki; Masayuki Yoshida
Journal:  BMC Nephrol       Date:  2013-10-07       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.